Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SHR-4602 injection in HER2-expressing or HER2-mutant unresectable or metastatic solid tumors
CTR20242442Phase 2Terminated
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Aug 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-4602 in Nonhematologic neoplasms, sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Aug 2024; status: terminated.
02
Drugs
SHR-4602
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20242442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242442.